CreativeOne Wealth LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX

CreativeOne Wealth LLC trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 54.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,310 shares of the pharmaceutical company’s stock after selling 2,723 shares during the quarter. CreativeOne Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $905,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of VRTX. Korea Investment CORP boosted its stake in Vertex Pharmaceuticals by 2.0% during the third quarter. Korea Investment CORP now owns 205,745 shares of the pharmaceutical company’s stock worth $80,578,000 after acquiring an additional 4,011 shares in the last quarter. Ameriflex Group Inc. increased its stake in shares of Vertex Pharmaceuticals by 255.6% during the third quarter. Ameriflex Group Inc. now owns 192 shares of the pharmaceutical company’s stock valued at $75,000 after purchasing an additional 138 shares in the last quarter. HUB Investment Partners LLC purchased a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $409,000. Legacy Capital Group California Inc. purchased a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $956,000. Finally, Modern Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 9.9% in the 3rd quarter. Modern Wealth Management LLC now owns 1,166 shares of the pharmaceutical company’s stock worth $456,000 after purchasing an additional 105 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ VRTX opened at $492.38 on Thursday. The firm has a market cap of $125.08 billion, a P/E ratio of 32.12 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The company has a 50 day moving average of $469.19 and a 200 day moving average of $436.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.98 earnings per share. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER data for povetacicept showed a large (~52%) reduction in proteinuria in IgA nephropathy, boosting hopes for an expedited regulatory filing and expansion of Vertex into kidney disease — a clear fundamental catalyst. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Positive Sentiment: Multiple banks raised price targets and reiterated Buy/Outperform ratings after the trial (Morgan Stanley, BofA, Oppenheimer, Citigroup, HC Wainwright, Truist, Jefferies, etc.), increasing analyst upside and supporting further gains. Analyst price target coverage roundup
• Positive Sentiment: Broker commentary and coverage upgrades (e.g., new coverage from Jefferies, maintained/raised ratings at BMO and others) reinforce investor confidence in povetacicept’s commercial potential and Vertex’s pipeline diversification. BMO Capital sticks to Buy rating
• Neutral Sentiment: Company presentations at healthcare conferences (Barclays, Leerink transcripts published) provide management commentary and additional detail for investors, but contain no new trial data beyond the RAINIER release. Barclays conference transcript
• Neutral Sentiment: Coverage in market media noted Vertex’s rising biotech weight in Nasdaq indices and broader attention following the trial — visibility that can attract flows but also raise short‑term trading interest. Biotech focus rises in Nasdaq index
• Negative Sentiment: After the big rally, the stock is pulling back (broader coverage flagged a larger intraday fall vs. the market); this looks like classic profit‑taking/mean reversion after rapid gains, increasing short‑term volatility risk. Vertex registers a bigger fall than the market
• Negative Sentiment: Zacks and other outlets also noted that recent earnings estimate revision trends and any lingering execution questions could temper momentum, so some analysts caution that the upside may be paced by upcoming filings and commercialization visibility. Will this strength last?

Insider Activity

In other Vertex Pharmaceuticals news, EVP Mark E. Bunnage sold 2,021 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the completion of the transaction, the executive vice president owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. The trade was a 13.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the transaction, the executive vice president owned 37,725 shares in the company, valued at $17,391,225. This represents a 20.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 91,156 shares of company stock valued at $42,845,497. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wells Fargo & Company upped their price target on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Barclays lifted their price objective on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an “overweight” rating in a research note on Tuesday, February 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $590.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research note on Tuesday, February 17th. Finally, HC Wainwright lifted their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a research report on Tuesday. Twenty-three analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $553.36.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.